UA83377C2 - N-гликозид, способ его получения, фармацевтическая композиция и способ лечения - Google Patents

N-гликозид, способ его получения, фармацевтическая композиция и способ лечения Download PDF

Info

Publication number
UA83377C2
UA83377C2 UAA200602256A UAA200602256A UA83377C2 UA 83377 C2 UA83377 C2 UA 83377C2 UA A200602256 A UAA200602256 A UA A200602256A UA A200602256 A UAA200602256 A UA A200602256A UA 83377 C2 UA83377 C2 UA 83377C2
Authority
UA
Ukraine
Prior art keywords
абоїа
aboia
aai
ааї
seiai
Prior art date
Application number
UAA200602256A
Other languages
English (en)
Ukrainian (uk)
Inventor
Тошияки Сакамото
Кийчиро Уета
Original Assignee
Мицубиши Танабе Фарма Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мицубиши Танабе Фарма Корпорейшн filed Critical Мицубиши Танабе Фарма Корпорейшн
Publication of UA83377C2 publication Critical patent/UA83377C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA200602256A 2003-08-01 2004-07-30 N-гликозид, способ его получения, фармацевтическая композиция и способ лечения UA83377C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49152303P 2003-08-01 2003-08-01
PCT/JP2004/011311 WO2005012321A1 (en) 2003-08-01 2004-07-30 Novel compounds

Publications (1)

Publication Number Publication Date
UA83377C2 true UA83377C2 (ru) 2008-07-10

Family

ID=34115512

Family Applications (5)

Application Number Title Priority Date Filing Date
UAA200605348A UA86042C2 (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides
UAA200605349A UA86599C2 (en) 2003-08-01 2004-07-30 Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
UAA200605347A UA85569C2 (ru) 2003-08-01 2004-07-30 Замещенные конденсированные гетероциклические с-гликозиды
UAA200605346A UA87991C2 (en) 2003-08-01 2004-07-30 Substituted indole-o-glucosides
UAA200602256A UA83377C2 (ru) 2003-08-01 2004-07-30 N-гликозид, способ его получения, фармацевтическая композиция и способ лечения

Family Applications Before (4)

Application Number Title Priority Date Filing Date
UAA200605348A UA86042C2 (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides
UAA200605349A UA86599C2 (en) 2003-08-01 2004-07-30 Substituted benzimidazole-, benztriazole- and benzimidazolone-о-glucosides
UAA200605347A UA85569C2 (ru) 2003-08-01 2004-07-30 Замещенные конденсированные гетероциклические с-гликозиды
UAA200605346A UA87991C2 (en) 2003-08-01 2004-07-30 Substituted indole-o-glucosides

Country Status (18)

Country Link
US (1) US7521430B2 (ru)
EP (1) EP1654269B1 (ru)
JP (1) JP4717811B2 (ru)
KR (1) KR101101500B1 (ru)
CN (2) CN1829728A (ru)
AU (1) AU2004260760B2 (ru)
BR (1) BRPI0413233A (ru)
CA (1) CA2534022C (ru)
EA (1) EA011025B1 (ru)
ES (1) ES2527053T3 (ru)
IL (1) IL173051A (ru)
MX (1) MXPA06001273A (ru)
NO (1) NO333679B1 (ru)
NZ (1) NZ545305A (ru)
TW (1) TWI377209B (ru)
UA (5) UA86042C2 (ru)
WO (1) WO2005012321A1 (ru)
ZA (2) ZA200601686B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2531660T3 (es) 2003-08-01 2015-03-18 Mitsubishi Tanabe Pharma Corporation Compuestos novedosos que tienen actividad inhibidora frente a transportador de glucosa dependiente de sodio
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
TWI365186B (en) 2005-01-31 2012-06-01 Mitsubishi Tanabe Pharma Corp Indole derivatives
JP5073948B2 (ja) * 2005-01-31 2012-11-14 田辺三菱製薬株式会社 医薬組成物
AR053329A1 (es) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co Derivados de indol utiles como inhibidores de los transportadores de glucosa dependientes del sodio (sglt)
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
NZ577391A (en) * 2006-12-04 2011-11-25 Janssen Pharmaceutica Nv Thienyl-containing glycopyranosyl derivatives as antidiabetics
UY30730A1 (es) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
RS56990B1 (sr) 2007-09-10 2018-05-31 Janssen Pharmaceutica Nv Postupak za dobijanje jedinjenja koja su korisna kao inhibitori sglt
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
US8791077B2 (en) 2008-05-22 2014-07-29 Astrazeneca Ab Method for treating hyperuricemia employing an SGLT2 inhibitor and composition containing same
AU2009286380B2 (en) 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
US20110230403A1 (en) * 2008-09-19 2011-09-22 Novartis Ag Glycoside derivatives and uses thereof
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
EP2451797B1 (en) 2009-07-10 2013-04-03 Janssen Pharmaceutica, N.V. CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE
HUE031375T2 (en) * 2009-10-14 2017-07-28 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
RS53827B1 (sr) 2009-11-02 2015-06-30 Pfizer Inc. Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
SG10201506114UA (en) 2010-05-11 2015-09-29 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt
EP2697218B1 (en) 2011-04-13 2016-05-25 Janssen Pharmaceutica NV Process for the preparation of compounds useful as inhibitors of sglt2
TWI542596B (zh) 2011-05-09 2016-07-21 健生藥品公司 （２ｓ,３ｒ,４ｒ,５ｓ,６ｒ）－２－（３－（（５－（４－氟苯基）噻吩－２－基）甲基）－４－甲基苯基）－６－（羥甲基）四氫－２ｈ－哌喃－３,４,５－三醇之ｌ－脯胺酸及檸檬酸共晶體
JP6173427B2 (ja) * 2013-02-26 2017-08-02 田辺三菱製薬株式会社 α−ハロテトラアシルグルコースの製造方法
CN103896930B (zh) * 2014-04-02 2016-08-17 安徽联创生物医药股份有限公司 卡格列净半水合物药用晶型的制备方法
ES2711804T3 (es) 2014-05-27 2019-05-07 Glenmark Pharmaceuticals Ltd Proceso para preparación de canagliflozina
CN104045673B (zh) * 2014-06-06 2017-01-18 安徽省食品药品检验研究院 双‑三氮唑缀合的假二糖衍生物及其制备方法
CN104478968A (zh) * 2015-01-14 2015-04-01 佛山市赛维斯医药科技有限公司 含噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN106188022A (zh) * 2015-04-30 2016-12-07 上海医药工业研究院 伊格列净的制备方法
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
CN111405899B (zh) 2017-11-30 2025-05-16 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合
MA53175A (fr) 2018-07-19 2021-05-26 Astrazeneca Ab Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci
CN116392472B (zh) 2020-07-27 2025-06-20 阿斯利康(瑞典)有限公司 用达格列净治疗慢性肾脏病的方法
US12409186B2 (en) 2020-07-27 2025-09-09 Astrazeneca Ab Methods of treating chronic kidney disease with dapagliflozin
EP4315350A1 (en) 2021-04-01 2024-02-07 AstraZeneca UK Limited Systems and methods for managing prediabetes with a gliflozin sodium-glucose cotransport 2 inhibitor pharmaceutical composition
US20250108065A1 (en) 2022-01-26 2025-04-03 Astrazeneca Ab Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
TW202525278A (zh) 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1075626B (de) * 1960-02-18 Farbwerke Hoechst Aktiengesellschaft vormals Meister Lucius &. Brunmg, Frankfurt/M Verfahren zur Herstellung von wasserlöslichen chemotherapeutisch wirksamen Glykosiden
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
NZ521369A (en) 2000-03-17 2004-07-30 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
SK287811B6 (sk) * 2000-09-29 2011-10-04 Kissei Pharmaceutical Co., Ltd Glukopyranozyloxybenzylbenzénový derivát, farmaceutická kompozícia a ľudský SGLT2-inhibítor tento derivát obsahujúci a použitie tohto derivátu
EP1344780A4 (en) * 2000-11-30 2004-01-28 Kissei Pharmaceutical GLUCOPYRANOSYLOXYBENZYLBENZOLE DERIVATIVES, MEDICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION
ATE431830T1 (de) 2000-12-28 2009-06-15 Kissei Pharmaceutical Glucopyranosylpyrazolderivate und deren verwendung in arzneimitteln
TWI255817B (en) * 2001-02-14 2006-06-01 Kissei Pharmaceutical Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
DE102004048388A1 (de) * 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
IL173051A (en) 2012-06-28
ES2527053T3 (es) 2015-01-20
TWI377209B (en) 2012-11-21
KR20060132539A (ko) 2006-12-21
CN102060888A (zh) 2011-05-18
UA87991C2 (en) 2009-09-10
NZ545305A (en) 2008-11-28
UA86042C2 (en) 2009-03-25
WO2005012321A1 (en) 2005-02-10
CA2534022C (en) 2012-10-02
EA011025B1 (ru) 2008-12-30
EA200600348A1 (ru) 2006-08-25
CN1829728A (zh) 2006-09-06
IL173051A0 (en) 2006-06-11
NO20060219L (no) 2006-04-28
EP1654269A1 (en) 2006-05-10
AU2004260760B2 (en) 2009-08-13
CA2534022A1 (en) 2005-02-10
JP4717811B2 (ja) 2011-07-06
JP2007518682A (ja) 2007-07-12
MXPA06001273A (es) 2006-04-11
UA86599C2 (en) 2009-05-12
ZA200603880B (en) 2010-01-27
US7521430B2 (en) 2009-04-21
ZA200601686B (en) 2007-05-30
EP1654269B1 (en) 2014-10-15
AU2004260760A1 (en) 2005-02-10
US20070060545A1 (en) 2007-03-15
TW200510440A (en) 2005-03-16
NO333679B1 (no) 2013-08-05
KR101101500B1 (ko) 2012-01-03
BRPI0413233A (pt) 2006-10-03
UA85569C2 (ru) 2009-02-10

Similar Documents

Publication Publication Date Title
UA83377C2 (ru) N-гликозид, способ его получения, фармацевтическая композиция и способ лечения
Laflamme et al. Incidence and risk factors of hemolysis after transcatheter aortic valve implantation with a balloon-expandable valve
Nikolajsen Missiologi i retrospektive og prospektive perspektiver
Hvidtfeldt Peter Kr. Iversen: Vejledning for sønderjyske lokalhistorikere (Skrifter, udg. af Historisk Samfund for Sønderjylland nr. 8).
Viklund et al. Luleå: De första 400 åren Volym 1
Dackling Familjejordbruk utan familjer? Syskonjordbruk på svensk landsbygd
US338823A (en) Peters
Hansen D. Pike: Australia: The Quiet Continent. Cambridge University Press, 1962. 242 s., ill. 13 X 19 cm. 22 sh. 6 d.
Masahito et al. Evaluation of implant-supported connecting crowns fabricated by optical and conventional impression methods
Jordaan Dr. PJ (Paul) Snyman 7 September 1930-31 Desember 2009: in dankbare herinnering
Slofstra O sjorem magaaije! Fiktyf Joadsk etnolekt yn'e Fryske literatuer.
US826366A (en) Automatic switch.
US1052248A (en) Railway-switch.
Koed MADS IVERSEN: Penge, Bank-og Børsvæsen.(GEC Gads Forlag, København 1930, 269 Sider).
Laval et al. Influence of soccer practice in the quality of life in adult men and women
Jacobs ONZE JOHANNES: OP ZOEK NAAR DE IDENTITEIT VAN EEN 18e-EEUWS CHINEES PORTRETBEELD VAN KLEI
Walsh Tetradius and the demoniac: radical shifts of focus in Jordaens’s Saint Martin healing a possessed man
Najdanović et al. Trend of delivery in Zajecar maternity hospital from 1961 to 2016
US692050A (en) Automatic switch-controller.
Corbett et al. Regurgitant Commissure Flow Through a Closed Polymeric Heart Valve
Liu et al. Influence of thickness and width of bioabsorbable vascular stent on local hemodynamics
Lauridsen Mogens Lebech: Danske Købstæder for to hundrede År siden og i Dag. Forudsætninger og Tilstande i Billeder og Tekst. I-11.(Udgivet på 200-årsdagen for oprettelsen af Købstædernes almindelige Brandforsikring 13. januar 1961). 304 og 208 s.
US693384A (en) Railroad-switch.
Bille Endnu et lille Bidrag til Martsdagenes Historie.
US988073A (en) Automatic railway-switch.